Is quetiapine safe to use as needed (PRN) on the day of induction of labor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Quetiapine PRN on Day of Labor Induction: Not Recommended

I strongly advise against using quetiapine PRN on the day of labor induction due to significant neonatal safety concerns and lack of data on acute peripartum use. The FDA explicitly warns that neonates exposed to antipsychotics (including quetiapine) during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery, with complications ranging from self-limited to requiring intensive care unit support and prolonged hospitalization 1.

Critical Safety Concerns

Immediate Neonatal Risks

The FDA label clearly states that third-trimester exposure to quetiapine puts neonates at risk for:

  • Extrapyramidal symptoms (hypertonia, tremor)
  • Withdrawal symptoms (agitation, somnolence, respiratory distress)
  • Feeding disorders
  • Potential need for NICU admission and prolonged hospitalization 1

These risks are particularly concerning when administering the medication acutely on the day of delivery, as the neonate will have peak maternal drug levels at birth with no time for gradual adaptation.

Maternal Risks During Labor

Quetiapine carries specific risks that are problematic during labor and delivery:

  • Orthostatic hypotension: In emergency settings, 40% of patients developed orthostasis within 2 hours, with 25% experiencing clinically significant symptoms 2. This is particularly dangerous during labor when volume status may be compromised.
  • Unknown effects on labor: The FDA explicitly states "the effect of quetiapine on labor and delivery in humans is unknown" 1
  • Increased postpartum bleeding: Quetiapine use during pregnancy is associated with increased postpartum bleeding risk (aOR 1.65) 3

Evidence Quality and Context

The available evidence does not support acute PRN use on the day of delivery:

  • Pregnancy safety data focuses on chronic use throughout pregnancy, not acute peripartum administration 4, 5
  • No major teratogenicity has been found with first-trimester exposure (1.3% malformation rate vs 1.4% in controls) 5, but this is irrelevant for day-of-delivery use
  • Metabolic risks (gestational diabetes, large-for-gestational-age infants) are associated with chronic use 6, not single-dose administration

Critical Gap in Evidence

None of the provided evidence addresses the specific clinical scenario of PRN quetiapine administration on the day of labor induction. The FDA pregnancy category C designation means quetiapine "should be used during pregnancy only if the potential benefit justifies the potential risk" 1—a threshold unlikely to be met for PRN anxiolysis when safer alternatives exist.

Recommended Alternatives

For acute anxiety or agitation on the day of labor induction, consider:

  • Non-pharmacologic interventions first (labor support, breathing techniques, environmental modifications)
  • Short-acting benzodiazepines if pharmacologic intervention is absolutely necessary (though these also carry neonatal risks, they have more predictable kinetics and established peripartum use)
  • Consultation with psychiatry if the patient has severe psychiatric illness requiring antipsychotic management

Common Pitfalls to Avoid

  1. Assuming pregnancy safety data applies to acute peripartum use: Chronic exposure data cannot be extrapolated to predict outcomes from acute administration hours before delivery
  2. Underestimating neonatal withdrawal risk: The FDA warnings about neonatal complications are based on third-trimester exposure, which includes the peripartum period
  3. Ignoring orthostatic hypotension risk: Labor patients may be volume-depleted, making orthostasis more likely and more dangerous

Bottom Line

The risk-benefit ratio does not favor quetiapine PRN use on the day of labor induction. The combination of unpredictable effects on labor, significant neonatal withdrawal/adaptation risks, and maternal orthostatic hypotension risk outweighs potential benefits for routine anxiety management. If the patient has been on chronic quetiapine therapy, continuing her established dose may be appropriate after psychiatric consultation, but initiating PRN use on the day of delivery is not supported by available evidence and carries unacceptable risks.

References

Related Questions

Is quetiapine (Seroquel) safe for use during pregnancy, and what are the fetal and maternal risks, recommended dosing, and monitoring guidelines?
Is quetiapine (Seroquel) safe to use during pregnancy?
Can quetiapine (Seroquel) be prescribed to a patient who is 7–8 weeks pregnant with bipolar disorder?
What is the bleeding risk associated with quetiapine (Seroquel)?
What are the risks and recommendations for combining 25 mg of Seroquel (quetiapine) and 20 mg of Latuda (lurasidone) with mirtazapine on board?
Based on MRI showing a hyperplastic central glandular mass, a heterogeneous nodule with capsules, a 10 mm circumscribed T2‑hypointense lesion with moderate diffusion restriction and early contrast enhancement in the left base transition zone anterior (PI‑RADS 4), and a similar 14 mm lesion in the left middle transition zone peripheral, is this description consistent with Prostate Imaging Reporting and Data System (PI‑RADS) category 4 or category 3?
What peer‑reviewed studies compare nebulized epinephrine (adrenaline) with systemic tranexamic acid for the management of hemoptysis?
What are the recommended methotrexate dosing adjustments based on estimated creatinine clearance?
Can sorbitol, peppermint, natural flower extracts, magnesium stearate (Vogetobia source), alcohol, and stevia cause false‑positive or elevated breath alcohol readings?
What is the appropriate intravenous dose of hydromorphone (Dilaudid) for an adult patient?
What is the most likely diagnosis and recommended diagnostic and management plan for a patient with bilateral renal masses and a pancreatic cyst?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.